Table 2.
Clinical profile and laboratory data for cases divided into groups based on the maximum shrinkage rate of the tumor blood vessel (TBV) diameter
| Tumor characteristicsa, b | Maximum shrinkage rate of TBV diameter ≥20% (n = 19) | Maximum shrinkage rate of TBV diameter <20% (n = 7) | p value |
|---|---|---|---|
| Largest tumor diameter, mm | 53.8 (30–127) | 62.5 (37.6–90) | 0.563 |
| TBV diameter before lenvatinib treatment, mm | 2.95 (1.85–4.83) | 2.23 (1.67–2.55) | 0.775 |
| Macrovascular invasion, n (%) | 9 (47) | 4 (57) | 0.500 |
| Extrahepatic metastasis, n (%) | 5 (26) | 1 (14) | 1.000 |
| BCLC stage B:C | 6:13 | 3:4 | 0.661 |
| TACE failure/refractoriness, n (%) | 10 (53) | 4 (57) | 1.000 |
a
BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization; TBV, tumor blood vessel. Data expressed as median (range).